When metformin cannot maintain glycemic control, sulfonylureas are often used as add-on therapy in type 2 diabetes; however, risks include weight gain and hypoglycemia. Dapagliflozin is an SGLT2 inhibitor and increases urinary glucose excretion and reduces hyperglycemia independently of insulin secretion or action.
When metformin cannot maintain glycemic control, sulfonylureas are often used as add-on therapy in type 2 diabetes; however, risks include weight gain and hypoglycemia, according to research presented in June at the American Diabetes Association 73rd Scientific Sessions, in Chicago. Dapagliflozin is an SGLT2 inhibitor and increases urinary glucose excretion and reduces hyperglycemia independently of insulin secretion or action.
A recent international, 52-week, double-blind, active-controlled, non-inferiority trial randomized patients who were inadequately controlled on metformin: 406 patients were given add-on dapagliflozin ≤10mg/d and 408 patients were given glipizide ≤20 mg/d. Patients were maintained to Week 52 unless hypoglycemia warranted down-titration.
At Week 52, 3 times more patients treated with dapagliflozin achieved combined HbA1C and weight reduction (66.9%) compared with patients taking glipizide (21.3%). Most patients taking dapagliflozin (74.7%) and glipizide (73.8%) achieved an HbA1C reduction, while 83.5% of patients taking dapagliflozin also experience weight reduction compared with only 26.8% of patients taking glipizide. Additionally, only 3.5% of patients taking dapagliflozin experienced hypoglycemic events, compared with 40.8% of patients taking glipizide.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More